PMID- 21857974 OWN - NLM STAT- MEDLINE DCOM- 20120215 LR - 20211020 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 6 IP - 8 DP - 2011 TI - Brain-derived neurotrophic factor in patients with Huntington's disease. PG - e22966 LID - 10.1371/journal.pone.0022966 [doi] LID - e22966 AB - Reduced Brain-Derived Neurotrophic Factor (BDNF) levels have been described in a number of patho-physiological conditions, most notably, in Huntington's disease (HD), a progressive neurodegenerative disorder. Since BDNF is also produced in blood, we have undertaken the measurement of its peripheral levels in the attempt to identify a possible link with HD prognosis and/or its progression. Here we evaluated BDNF level in 398 blood samples including 138 controls, 56 preHD, and 204 HD subjects. We found that BDNF protein levels were not reliably different between groups, whether measured in plasma (52 controls, 26 preHD, 105 HD) or serum (39 controls, 5 preHD, 29 HD). Our experience, and a re-analysis of the literature highlighted that intra-group variability and methodological aspects affect this measurement, especially in serum. We also assessed BDNF mRNA levels in blood samples from 47 controls, 25 preHD, and 70 HD subjects, and found no differences among the groups. We concluded that levels of BDNF in human blood were not informative (mRNA levels or plasma protein level) nor reliable (serum protein levels) as HD biomarkers. We also wish to warn the scientific community in interpreting the significance of changes measured in BDNF protein levels in serum from patients suffering from different conditions. FAU - Zuccato, Chiara AU - Zuccato C AD - Department of Pharmacological Sciences and Center for Stem Cell Research, Universita degli Studi di Milano, Milan, Italy. FAU - Marullo, Manuela AU - Marullo M FAU - Vitali, Barbara AU - Vitali B FAU - Tarditi, Alessia AU - Tarditi A FAU - Mariotti, Caterina AU - Mariotti C FAU - Valenza, Marta AU - Valenza M FAU - Lahiri, Nayana AU - Lahiri N FAU - Wild, Edward J AU - Wild EJ FAU - Sassone, Jenny AU - Sassone J FAU - Ciammola, Andrea AU - Ciammola A FAU - Bachoud-Levi, Anne Catherine AU - Bachoud-Levi AC FAU - Tabrizi, Sarah J AU - Tabrizi SJ FAU - Di Donato, Stefano AU - Di Donato S FAU - Cattaneo, Elena AU - Cattaneo E LA - eng GR - Department of Health/United Kingdom PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20110812 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (ANXA10 protein, human) RN - 0 (Annexins) RN - 0 (Antidepressive Agents, Tricyclic) RN - 0 (Antipsychotic Agents) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Neurotransmitter Uptake Inhibitors) RN - 0 (RNA, Messenger) RN - 12794-10-4 (Benzodiazepines) RN - EC 2.7.11.1 (ROCK1 protein, human) RN - EC 2.7.11.1 (rho-Associated Kinases) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Annexins/genetics MH - Antidepressive Agents, Tricyclic/therapeutic use MH - Antipsychotic Agents/therapeutic use MH - Benzodiazepines/therapeutic use MH - Brain-Derived Neurotrophic Factor/*blood/*genetics MH - Cohort Studies MH - Enzyme-Linked Immunosorbent Assay MH - Female MH - France MH - Gene Expression MH - Humans MH - Huntington Disease/*blood/drug therapy/*genetics MH - Italy MH - London MH - Male MH - Middle Aged MH - Neurotransmitter Uptake Inhibitors/therapeutic use MH - RNA, Messenger/genetics/metabolism MH - Reverse Transcriptase Polymerase Chain Reaction MH - Young Adult MH - rho-Associated Kinases/genetics PMC - PMC3155522 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2011/08/23 06:00 MHDA- 2012/02/16 06:00 PMCR- 2011/08/12 CRDT- 2011/08/23 06:00 PHST- 2011/05/24 00:00 [received] PHST- 2011/07/03 00:00 [accepted] PHST- 2011/08/23 06:00 [entrez] PHST- 2011/08/23 06:00 [pubmed] PHST- 2012/02/16 06:00 [medline] PHST- 2011/08/12 00:00 [pmc-release] AID - PONE-D-11-09103 [pii] AID - 10.1371/journal.pone.0022966 [doi] PST - ppublish SO - PLoS One. 2011;6(8):e22966. doi: 10.1371/journal.pone.0022966. Epub 2011 Aug 12.